Progression‐free survival · people with metastatic CRC
Modern chemotherapy regimens leads to lower progression‐free survival compared with 5‐flourouracil (high certainty).
1 finding from 1 review
Tumour response · people with metastatic CRC
Modern chemotherapy regimens leads to higher overall tumour response compared with 5‐flourouracil (high certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Modern chemotherapy regimens probably leads to higher severe adverse effects compared with 5‐flourouracil (moderate certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Irinotecan + targeted therapy showed no clear difference in overall survival compared with irinotecan (low certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic CRC
Irinotecan + targeted therapy probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
1 finding from 1 review
Tumour response · people with metastatic CRC
Irinotecan + targeted therapy leads to higher overall tumour response compared with irinotecan (high certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Irinotecan + targeted therapy leads to higher severe adverse effects compared with irinotecan (high certainty).
1 finding from 1 review
NON ‐ Healing (persistence or recurrence) · people with anal fissures
Any Surgery leads to lower NON ‐ Healing (persistence or recurrence) compared with any Medical Therapy (high certainty).
1 finding from 1 review
Physical function · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review
Disease‐related mental health: depression · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review
Disease‐related mental health: anxiety · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review
Overall survival (time interval between enrolment in the study and death of the person from any cause) · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence‐free survival · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review
Physical fitness: aerobic fitness · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review
Cancer‐related fatigue · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review
Health‐related quality of life (HRQoL) · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review
Disease-free survival · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral showed no clear difference in disease‐free survival compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral may leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review
Overall survival · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).
1 finding from 1 review